1-6 of 6
Alison Stopeck
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer

Elena Shagisultanova, William Gradishar, Ursa Brown-Glaberman, Pavani Chalasani, Andrew J. Brenner, Alison Stopeck, Hannah Parris, Dexiang Gao, Tessa McSpadden, Jose Mayordomo, Jennifer R. Diamond, Peter Kabos, Virginia F. Borges
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (24): 5021–5030.
https://doi.org/10.1158/1078-0432.CCR-23-0117
Published: 15 December 2023
View article titled, Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
Open the PDF for Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid

Miguel Martin, Richard Bell, Hugues Bourgeois, Adam Brufsky, Ingo Diel, Alexandru Eniu, Lesley Fallowfield, Yasuhiro Fujiwara, Jacek Jassem, Alexander H.G. Paterson, Diana Ritchie, Günther G. Steger, Alison Stopeck, Charles Vogel, Michelle Fan, Qi Jiang, Karen Chung, Roger Dansey, Ada Braun
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4841–4849.
https://doi.org/10.1158/1078-0432.CCR-11-3310
Published: 30 August 2012
View article titled, Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid
Open the PDF for Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid in another window
Journal Articles

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

Shanu Modi, Alison Stopeck, Hannah Linden, David Solit, Sarat Chandarlapaty, Neal Rosen, Gabriella D'Andrea, Maura Dickler, Mary E. Moynahan, Steven Sugarman, Weining Ma, Sujata Patil, Larry Norton, Alison L. Hannah, Clifford Hudis
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (15): 5132–5139.
https://doi.org/10.1158/1078-0432.CCR-11-0072
Published: 31 July 2011
View article titled, HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
Open the PDF for HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival

Daniel F. Hayes, Massimo Cristofanilli, G. Thomas Budd, Matthew J. Ellis, Alison Stopeck, M. Craig Miller, Jeri Matera, W. Jeffrey Allard, Gerald V. Doyle, Leon W.W.M. Terstappen
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4218–4224.
https://doi.org/10.1158/1078-0432.CCR-05-2821
Published: 20 July 2006
View article titled, Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival
Open the PDF for Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival in another window
Journal Articles

Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma

Maurizio Zangari, Elias Anaissie, Alison Stopeck, Alyssa Morimoto, Nguyen Tan, Jeffrey Lancet, Maureen Cooper, Alison Hannah, Guillermo Garcia-Manero, Stephan Faderl, Hagop Kantarjian, Julie Cherrington, Maher Albitar, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (1): 88–95.
https://doi.org/10.1158/1078-0432.CCR-0221-3
Published: 20 January 2004
View article titled, Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma
Open the PDF for Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma in another window
Journal Articles

Results of a Phase I Dose-escalating Study of the Antiangiogenic Agent, SU5416, in Patients with Advanced Malignancies

Alison Stopeck, Marrae Sheldon, Mahmood Vahedian, Gillian Cropp, Rishi Gosalia, Alison Hannah
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (9): 2798–2805.
Published: 01 September 2002
View article titled, Results of a Phase I Dose-escalating Study of the Antiangiogenic Agent, SU5416, in Patients with Advanced Malignancies
Open the PDF for Results of a Phase I Dose-escalating Study of the Antiangiogenic Agent, SU5416, in Patients with Advanced Malignancies in another window